Evaluation of TP53 Pro72Arg and MDM2 SNP285–SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations
- 211 Downloads
Li-Fraumeni syndrome (LFS) is a rare genetic cancer predisposition disease, partly determined by the presence of a TP53 germline mutation; lacking thereof, in presence of a typical LFS phenotype, defines a wide group of ‘LFS Suggestive’ patients. Alternative LFS susceptibility genes have been investigated without promising results, thus suggesting other genetic determinants involvement in cancer predisposition. Hence, this study explores the single and combined effects of cancer risk, age of onset and cancer type of three single nucleotide polymorphisms (SNPs)—TP53 Pro72Arg, MDM2 SNP285 and SNP309—already described as modifiers on TP53 mutation carriers but not properly investigated in LFS Suggestive patients. This case–control study examines 34 Italian LFS Suggestive lacking of germline TP53 mutations and 95 tumour-free subjects. A significant prevalence of homozygous MDM2 SNP309 G in the LFS Suggestive group (p < 0.0005) confirms its contribute to cancer susceptibility, also highlighted in LFS TP53 positive families. Conversely its anticipating role on tumour onset has not been confirmed, as in our results it was associated with the SNP309 T allele. A strong combined outcome with a ‘dosage’ effect has also been reported for TP53 P72 and MDM2 SNP309 G allele on cancer susceptibility (p < 0.0005). Whereas the MDM2 SNP285 C allele neutralizing effect on MDM2 SNP309 G variant is not evident in our population. Although it needs further evaluations, obtained results strengthen the role of MDM2 SNP309 as a genetic factor in hereditary predisposition to cancer, so improving LFS Suggestive patients management.
KeywordsSuggestive of Li-Fraumeni syndrome TP53 Pro72Arg MDM2 SNP285 MDM2 SNP309 Rare disease Osteosarcoma
The authors wish to thank all patients and parents for valuable contribution to the study, the BIOGEN Biobank for granting access to samples and their related clinical informations and Dr. Elettra Pignotti for her fundamental contribution to the statistical data analysis. A special acknowledgment goes to Dr Gareth Bond and his group (Ludwig Institute for Cancer Research, University of Oxford, UK) for their helpful suggestions on the manuscript and supporting the genotyping validation.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 6.Tinat J, Bougeard G, Baert-Desurmont S, Vasseur S, Martin C, Bouvignies E, Caron O, Bressac-de Paillerets B, Berthet P, Dugast C, Bonaïti-Pellié C, Stoppa-Lyonnet D, Frébourg T (2009) 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 27(26):e108-9;author reply e110. doi: 10.1200/JCO.2009.22.7967
- 12.Renaux-Petel M, Sesboue R, Baert-Desurmont S, Vasseur S, Fourneaux S, Bessenay E, Frébourg T, Bougeard G (2014) The MDM2 285G-309G haplotype is associated with an earlier age of tumor onset in patients with Li Fraumeni Syndrome. Fam cancer 13(1):127–130. doi: 10.1007/s10689-013-9667-2 CrossRefPubMedGoogle Scholar
- 24.Epistolato MC, Disciglio V, Livide G, Berchialla P, Mencarelli MA, Marozza A, Amenduni M, Hadjistilianou T, De Francesco S, Acquaviva A, Toti P, Cetta F, Ariani F, De Marchi M, Renieri A, Giachino D (2011) p53 Arg72Pro and MDM2 309 SNPs in hereditary retinoblastoma. JMG 53:685–686. doi: 10.3810/jhg.2011.82 Google Scholar
- 25.Menin C, Scaini MC, De Salvo GL, Biscuola M, Quaggio M, Esposito G, Belluco C, Montagna M, Agata S, D’Andrea E, Nitti D, Amadori A, Bertorelle R (2006) Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 98(4):285–288CrossRefPubMedGoogle Scholar
- 27.Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L, Chompret A, Bressac-de Paillerets B, Stoppa-Lyonnet D, Bonaiti-Pellie C, Frebourg T (2006) Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 43(6):531–533CrossRefPubMedGoogle Scholar
- 31.Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, Scott RJ (2007) MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients. Int J Cancer 120(3):563–565CrossRefPubMedGoogle Scholar
- 36.Gansmo LB, Knappskog S, Romundstd P, Hveem K, Vatten L, Lonning PE (2015) Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon. Int J 137:96–103Google Scholar